Factors associated with hospitalizations for Covid-19 in patients with rheumatoid arthritis: data from the Reumacov Brazil registry
-
Published:2022-05-03
Issue:1
Volume:62
Page:
-
ISSN:2523-3106
-
Container-title:Advances in Rheumatology
-
language:en
-
Short-container-title:Adv Rheumatol
Author:
Gomides Ana Paula MonteiroORCID, de Albuquerque Cleandro Pires, da Mota Licia Maria Henrique, Devidé Guilherme, Dias Laiza Hombre, Duarte Angela Luzia Branco Pinto, Giovelli Raquel Altoé, Karnopp Thais Evelyn, de Lima Hugo Deleon, Marinho Adriana, de Oliveira Marianne Schrader, Omura Felipe, Ranzolin Aline, Resende Gustavo, Ribeiro Francinne Machado, Ribeiro Sandra Lúcia Euzébio, de Carvalho Sacilotto Nathália, dos Santos Wander Gonzaga, Shinjo Samuel Katsuyuki, de Sousa Studart Samia Araujo, Teixeira Flávia Patricia Sena, Yazbek Michel Alexandre, Ferreira Gilda Aparecida, Monticielo Odirlei A., Paiva Eduardo, Pileggi Gecilmara Cristina Salviato, dos Reis-Neto Edgard Torres, de Medeiros Pinheiro Marcelo, Marques Claudia D. L.,
Abstract
Abstract
Background
Patients using immunosuppressive drugs may have unfavorable results after infections. However, there is a lack of information regarding COVID-19 in these patients, especially in patients with rheumatoid arthritis (RA). Therefore, the aim of this study was to evaluate the risk factors associated with COVID-19 hospitalizations in patients with RA.
Methods
This multicenter, prospective cohort study is within the ReumaCoV Brazil registry and included 489 patients with RA. In this context, 269 patients who tested positive for COVID-19 were compared to 220 patients who tested negative for COVID-19 (control group). All patient data were collected from the Research Electronic Data Capture database.
Results
The participants were predominantly female (90.6%) with a mean age of 53 ± 12 years. Of the patients with COVID-19, 54 (20.1%) required hospitalization. After multiple adjustments, the final regression model showed that heart disease (OR = 4.61, 95% CI 1.06–20.02. P < 0.001) and current use of glucocorticoids (OR = 20.66, 95% CI 3.09–138. P < 0.002) were the risk factors associated with hospitalization. In addition, anosmia was associated with a lower chance of hospitalization (OR = 0.26; 95% CI 0.10–0.67, P < 0.005).
Conclusion
Our results demonstrated that heart disease and the use of glucocorticoids were associated with a higher number of hospital admissions for COVID-19 in patients with RA.
Trial registration: Brazilian Registry of Clinical Trials - RBR-33YTQC.
Funder
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Publisher
Springer Science and Business Media LLC
Reference55 articles.
1. D’Antiga L. Coronaviruses and immunosuppressed patients: the facts during the third epidemic. Liver Transpl. 2020;26:832–4. 2. Venerito V, Lopalco G, Iannone F. COVID-19, rheumatic diseases and immunosuppressive drugs: an appeal for medication adherence. Rheumatol Int. 2020;40:827–8. 3. Falagas ME, Manta KG, Betsi GI, Pappas G. Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review. Clin Rheumatol. 2007;26:663–70. 4. Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R. COVID-19 infection and rheumatoid arthritis: Faraway, so close! Autoimmun Rev. 2020;19:102523. 5. D’Silva KM, Serling-Boyd N, Wallwork R, Hsu T, Fu X, Gravallese EM, Clinical characteristics and outcomes of patients with coronavirus disease, et al. (COVID-19) and rheumatic disease: a comparative cohort study from a US ‘hot spot.’ Ann Rheum Dis. 2019;79:1156–62.
|
|